Introduction to Bosutinib (Bosulf)

Bosutinib, trade nameBosulif, is a targeted therapy drug for chronic myelogenous leukemia (CML). As a small molecule BCR-ABL and Src tyrosine kinase inhibitor, bosutinib was originally synthesized by Wyeth and is now further developed by Pfizer. It plays an important role in the field of leukemia treatment.

Bosutinib is an ATP-competitive Bcr-Abl tyrosine kinase inhibitor that not only effectively inhibits the activity of BCR-ABL, but also has additional inhibitory effects on Src family kinases (such as Src, Lyn and Hck). In addition, it can inhibit platelet-derived growth factor and vascular endothelial growth factor receptor, providing a multi-faceted mechanism of action for the treatment of chronic myelogenous leukemia.

Bosutinib is a prescription drug specifically indicated clinically for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), whether they are newly diagnosed or are resistant or intolerant to previous treatments. In addition, bosutinib also has significant efficacy in adult patients with Ph+ CML who are in the accelerated phase or blast phase and are resistant or intolerant to previous treatments However, patients need to closely monitor their medical condition and drug response during treatment with bosutinib. If you experience any uncomfortable symptoms or adverse reactions, please seek medical treatment immediately and communicate with your doctor.

It is reported that the price of bosutinib varies depending on the version and region. The original drugs, including the Turkish version and the European version, are relatively expensive; while the generic drugs produced by Mylan in India are more affordable, with a box costing about more than 1,000 yuan. When choosing a version of a drug, patients should be sure to purchase it through regular channels to ensure the quality and safety of the drug.